论文部分内容阅读
目的探讨乳腺癌基质金属蛋白酶2(MMP2)mRNA表达量与乳腺癌转移的关系及临床意义。方法采用荧光定量逆转录聚合酶链反应(RT PCR)方法,检测30例乳腺原发癌和配对淋巴结转移癌以及116例乳腺原发癌的MMP2mRNA表达量,比较30例乳腺原发癌和配对淋巴结转移与116例乳腺原发癌的MMP2mRNA表达量,分析MMP2mRNA表达量与乳腺癌临床病理因素的关系。结果30例乳腺淋巴结转移癌MMP2mRNA表达量低于原发癌(t=-3.293,P<0.05)。肿瘤>2cm的MMP2mRNA表达量低于肿瘤≤2cm(t=1.936,P<0.05),临床Ⅱ期和Ⅲ期的MMP2mRNA表达量低于Ⅰ期(t=2.466,P<0.05),淋巴结4个以上阳性组MMP2mRNA表达量低于1～3个阳性组(t=3.202,P<0.05)。MMP2mRNA表达量与病理类型、组织学分级、雌、孕激素受体及Her2表达无关。结论MMP2mRNA表达量在临床早期及淋巴结转移早期上调,随着肿瘤的进展表达量下调。MMP2mRNA转录水平的表达与乳腺癌转移有关。
Objective To investigate the relationship between breast cancer matrix metalloproteinase 2 (MMP2) mRNA expression and breast cancer metastasis and its clinical significance. Methods The mRNA expression of MMP2 in 30 cases of primary breast cancer and paired lymph node metastasis and 116 cases of primary breast cancer was detected by fluorescence quantitative RT-PCR. Thirty cases of primary breast cancer and paired lymph node Metastasis and 116 cases of primary breast cancer MMP2mRNA expression, analysis of MMP2mRNA and breast cancer clinicopathological factors. Results The expression of MMP2 mRNA in breast cancer with lymph node metastasis was lower than that in primary cancer (t = -3.293, P <0.05). The expression of MMP2 mRNA in tumors> 2 cm was lower than that in tumor ≤ 2 cm (t = 1.936, P <0.05). The MMP2 mRNA expression in stage Ⅱ and Ⅲ was lower than that in stage Ⅰ (t = 2.466, The positive expression rate of MMP2mRNA was lower than 1 ~ 3positive group (t = 3.202, P <0.05). The expression of MMP2mRNA was not associated with pathological type, histological grade, estrogen and progesterone receptor and Her2 expression. Conclusion The expression of MMP2 mRNA is up-regulated early in clinical and early stage of lymph node metastasis, and down-regulated with the progress of tumor. The expression of MMP2 mRNA is related to the metastasis of breast cancer.